66%
SKYRIZI
Percentage of patients
doses per year
after 2 starter doses
SKYRIZI is a single injection
dosed every 12 weeks after
initiation
SKYRIZI vs Other Injections
SKYRIZI CAN OFFER BETTER SKIN CLEARANCE VS HUMIRA
In this study of 605 patients at 16 weeks, 72% of SKYRIZI patients saw 90% clearer skin, compared to 47% of HUMIRA patients, and 40% of SKYRIZI patients saw 100% clear skin, compared to 23% of HUMIRA patients.
At 16 weeks, some HUMIRA patients were switched to SKYRIZI and saw the following results at 44 weeks.*
3x higher percentage of patients achieved 90% clearer skin on SKYRIZI at 44 weeks
21%
HUMIRA
Percentage of patients
~6x higher percentage of patients achieved 100% clear skin on SKYRIZI at 44 weeks
40%
SKYRIZI
Percentage of patients
7%
HUMIRA
Percentage of patients
*At 16 weeks, 109 HUMIRA patients who had at least 50% but less than 90% clearer skin were either switched to SKYRIZI for 28 more weeks, or stayed on HUMIRA through the remainder of the study—a total of 44 weeks.
See how Paul achieved clearer skin by switching from HUMIRA to SKYRIZI
Time of video: 5:51
In this study of 327 patients,
MORE PATIENTS HAD CLEARER SKIN WITH SKYRIZI VS COSENTYX AT 1 YEAR
At 16 weeks, SKYRIZI was studied to show that it was similarly effective to Cosentyx. 74% of SKYRIZI patients and 66% of Cosentyx patients achieved 90% clearer skin at 16 weeks.
>1.5x higher percentage of patients achieved 90% clearer skin on SKYRIZI at 1 year
87%
SKYRIZI
Percentage of patients
57%
Cosentyx
Percentage of patients
>1.5x higher percentage of patients achieved 100% clear skin on SKYRIZI at 1 year
66%
SKYRIZI
Percentage of patients
40%
Cosentyx
Percentage of patients
COSENTYX® is a registered trademark of Novartis AG.
Patients were aware of the treatments they were taking, which may have influenced results.
In a study of 491 patients,
MORE PATIENTS ACHIEVED CLEARER SKIN WITH SKYRIZI VS STELARA
>1.5x higher percentage of patients achieved 90% clearer skin on SKYRIZI at 16 weeks
75%
SKYRIZI
Percentage of patients
47%
Stelara
Percentage of patients
>2x higher percentage of patients achieved 100% clear skin on SKYRIZI at 16 weeks
51%
SKYRIZI
Percentage of patients
24%
Stelara
Percentage of patients
In another study of 506 patients, 75% of SKYRIZI patients and 42% of Stelara patients achieved 90% clearer skin at 16 weeks. In the same study, 36% of SKYRIZI patients and 12% of Stelara patients achieved 100% clear skin at 16 weeks.
STELARA® is a registered trademark of Johnson & Johnson.
The patients in these studies received ustekinumab (known as Stelara) from outside of the United States (US). Similarities between ustekinumab approved in the US and ustekinumab approved in other countries has not been established.
YOUR YEAR-LONG DOSING SCHEDULE: SKYRIZI AND OTHER INJECTIONS
SKYRIZI
4
HUMIRA
25
doses per year
after 1 starter dose
HUMIRA is a single
injection dosed every
other week after initiation
COSENTYX
12
doses per year
after 5 starter doses
Cosentyx is 2 injections
dosed every 4 weeks
after initiation
STELARA
4
doses per year
after 2 starter doses
Stelara is a single injection
dosed every 12 weeks
after initiation
COSENTYX® is a registered trademark of Novartis AG.
STELARA® is a registered trademark of Johnson & Johnson.
